AC2592 + placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Congestive Heart Failure
Conditions
Congestive Heart Failure
Trial Timeline
Mar 1, 2005 → Sep 1, 2006
NCT ID
NCT00099580About AC2592 + placebo
AC2592 + placebo is a phase 2 stage product being developed by AstraZeneca for Congestive Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT00099580. Target conditions include Congestive Heart Failure.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00099580 | Phase 2 | Completed |
Competing Products
20 competing products in Congestive Heart Failure
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Seloken ZOK/Toprol-XL + Seloken ZOK/Toprol-XL + Placebo | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| Dapagliflozin + Placebo | AstraZeneca | Approved | 85 |
| Enoximone + Metoprolol succinate + Placebo to match enoximone + Placebo to match metoprolol succinate | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| Candesartan + Placebo | AstraZeneca | Phase 3 | 77 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| KW-3902IV | Merck | Phase 2 | 52 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| KW-3902IV | Merck | Phase 2 | 52 |
| Sitagliptin | Merck | Phase 1 | 33 |
| Low Dose Bisoprolol + High Dose Bisoprolol | Merck | Approved | 85 |
| rolofyline + Comparator Placebo (unspecified) | Merck | Phase 2 | 52 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| rolofylline + Comparator: Placebo (unspecified) | Merck | Phase 3 | 77 |
| vildagliptin + placebo of vildagliptin | Novartis | Approved | 85 |
| Relaxin + Placebo | Novartis | Phase 2/3 | 65 |
| Relaxin | Novartis | Phase 2 | 52 |